-
公开(公告)号：US20070048394A1
公开(公告)日：2007-03-01
申请号：US11215568
申请日：2005-08-29
申请人： Wen-Chin Yang , Shu-Lin Chang , Yi-Ming Chiang , Lie-Fen Shyur
发明人： Wen-Chin Yang , Shu-Lin Chang , Yi-Ming Chiang , Lie-Fen Shyur
CPC分类号： G01N33/505 , A61K36/28
摘要： Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN γ or IL-2 transcription.
摘要翻译： 方法可用于例如鉴定具有免疫调节活性的植物组合物。 还公开了可用于增加免疫应答例如IFNγ或IL-2转录的菊科植物免疫调节组合物。
-
公开(公告)号：US20080193432A1
公开(公告)日：2008-08-14
申请号：US11673433
申请日：2007-02-09
IPC分类号： A61K31/122 , C07D311/72 , A61K31/355 , C07C69/732 , C07J53/00 , A61P5/24 , A61K31/575 , A61K31/216 , C07D311/70 , C07C49/683
CPC分类号： C07J53/00 , C07C49/573 , C07C69/734 , C07D311/72
摘要： The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-α-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, γ-tocopherol-9, and analogues thereof. The compounds of the present invention activate ERα and ERβ, and express high estrogenic activity.
摘要翻译： 本发明提供具有雌激素活性的化合物，其选自RRR-α-生育酚，氢-9-色烯，辅酶Q 9，环亚烷，1-阿魏酸甘油 ，γ-生育酚-9及其类似物。 本发明化合物激活ERalpha和ERbeta，表达高雌激素活性。
-
公开(公告)号：US20070053998A1
公开(公告)日：2007-03-08
申请号：US11219503
申请日：2005-09-02
申请人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
发明人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
IPC分类号： A61K36/185
摘要： A compound of the formula: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; and p is 1, 2, 3, or 4. Also disclosed is use of the compound to inhibit Th1 differentiation, promote Th2 differentiation, and treat certain disorders.
摘要翻译： 下式的化合物：其中R 1是H，烷基，芳基或环基; R 2是吡喃糖; R 3是H或烷基; m为2,3,4,5或6; n为0,1,2或3; o是0，1，2，3，4; 并且p是1,2,3或4.还公开了该化合物用于抑制Th1分化，促进Th2分化和治疗某些疾病的用途。
-
公开(公告)号：US08048860B2
公开(公告)日：2011-11-01
申请号：US12263896
申请日：2008-11-03
申请人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
发明人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
IPC分类号： A61K31/7032 , C07G3/00 , C07H15/10
摘要： A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.
摘要翻译： 治疗Th1介导的病症的方法包括向需要治疗的受试者施用有效量的式I化合物：其中R 1是H，烷基，芳基或环基; R2是吡喃糖; R3是H或烷基; m为2,3,4,5或6; n为0,1,2或3; o是0，1，2，3，4; p是1,2,3或4; 并且Th1介导的病症是非肥胖性糖尿病，克罗恩病的结肠炎，自身免疫性溶血性贫血，类风湿性关节炎，自身免疫性脑炎，多发性硬化或自身免疫性心肌炎。 还公开了包含上述式I化合物和药学上可接受的载体的药物组合物。
-
公开(公告)号：US07691575B2
公开(公告)日：2010-04-06
申请号：US11215568
申请日：2005-08-29
申请人： Wen-Chin Yang , Shu-Lin Chang , Yi-Ming Chiang , Lie-Fen Shyur
发明人： Wen-Chin Yang , Shu-Lin Chang , Yi-Ming Chiang , Lie-Fen Shyur
CPC分类号： G01N33/505 , A61K36/28
摘要： Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN γ or IL-2 transcription.
摘要翻译： 方法可用于例如鉴定具有免疫调节活性的植物组合物。 还公开了可用于增加免疫应答例如IFNγ或IL-2转录的菊科植物免疫调节组合物。
-
公开(公告)号：US20240150803A1
公开(公告)日：2024-05-09
申请号：US18380447
申请日：2023-10-16
申请人： Berl OAKLEY , Travis J. WILLIAMS , Yi-Ming CHIANG , Clay C. WANG , Yuhao CHEN , Swati BIJLANI , C. Elizabeth OAKLEY , Christian Anthony RABOT
发明人： Berl OAKLEY , Travis J. WILLIAMS , Yi-Ming CHIANG , Clay C. WANG , Yuhao CHEN , Swati BIJLANI , C. Elizabeth OAKLEY , Christian Anthony RABOT
CPC分类号： C12P17/162 , B01J27/24 , B01J31/0244 , B01J31/0247 , B01J31/2208 , C12N9/1051 , C12N15/52 , C12P7/26 , C12Y204/01183 , B01J2231/70 , B01J2531/72 , B01J2531/842 , B01J2531/845
摘要： A non-human organism for upgrading intermediate oxidation products formed by catalytic degradation of alkanes or polystyrenes is provided. The non-human organism is genetically modified to convert the intermediate oxidation products to secondary metabolites, and in particular to include a positive feedback loop construction in the promotor system. A method includes steps of catalytically degrading alkanes or polystyrene in an oxidizing environment to form intermediate products with one or more catalysts and contacting the intermediate products with the non-human organism such that intermediate oxidation products are converted to secondary metabolites.
-
公开(公告)号：US07999004B2
公开(公告)日：2011-08-16
申请号：US11673433
申请日：2007-02-09
IPC分类号： C07D311/00 , A61K31/355
CPC分类号： C07J53/00 , C07C49/573 , C07C69/734 , C07D311/72
摘要： The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-α-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, γ-tocopherol-9, and analogues thereof. The compounds of the present invention activate ERα and ERβ, and express high estrogenic activity.
摘要翻译： 本发明提供具有选自RRR-α-生育酚，氢-Q9色烯，辅酶Q9，环亚烷，1-阿魏酰甘油，γ-生育酚-9及其类似物的雌激素活性的化合物。 本发明化合物激活ERα和ER＆bgr，并表达高雌激素活性。
-
公开(公告)号：US20090062216A1
公开(公告)日：2009-03-05
申请号：US12263896
申请日：2008-11-03
申请人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
发明人： Wen-Chin Yang , Shu-Lin Chang , Lee-Tian Chang , Yi-Ming Chiang , Lie-Fen Shyur
IPC分类号： A61K31/7028 , A61P37/00
摘要： A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.
摘要翻译： 治疗Th1介导的病症的方法包括向需要治疗的受试者施用有效量的式I化合物：其中R 1是H，烷基，芳基或环基; R2是吡喃糖; R3是H或烷基; m为2,3,4,5或6; n为0,1,2或3; o是0，1，2，3，4; p是1,2,3或4; 并且Th1介导的病症是非肥胖性糖尿病，克罗恩病的结肠炎，自身免疫性溶血性贫血，类风湿性关节炎，自身免疫性脑炎，多发性硬化或自身免疫性心肌炎。 还公开了包含上述式I化合物和药学上可接受的载体的药物组合物。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.025 秒)
